7 Aug 2025
August Investment Review
In this article, we highlight the top 10 performers of Global X ETFs over the past three months. By the end of July, China Biotech ETF (2820 HK), AI &… By Lizzy Liu
Thoroughly researched perspectives and commentary on the trends shaping global markets. Subscribe to Updates →
Exploring a range of subjects as diverse as our product lineup.
7 Aug 2025
In this article, we highlight the top 10 performers of Global X ETFs over the past three months. By the end of July, China Biotech ETF (2820 HK), AI &… By Lizzy Liu
2 Jun 2025
Global X China Biotech ETF (2820/9820) recorded strong return YTD and is among the best-performing China thematic ETFs. As we outlined in April, we believe biotech sector is showing signs… By Jeff Huang
14 May 2025
The US and China have announced to temporarily lower tariffs for 90 days (Link), with the US cutting its duties on most Chinese imports from 145% to 30%, and China… By Lizzy Liu
20 Feb 2025
As we enter 2025, the rise of Chinese companies in cutting-edge technology sectors such as AI, humanoid robots, and autonomous driving is gaining global attention to China’s innovation capabilities, and… By Jeff Huang
20 Feb 2025
On 17 Feb 2025, President Xi convened an unusual meeting with leading entrepreneurs mainly from major tech and advanced manufacturing companies. Several Global X China theme ETFs – China EV… By Lizzy Liu
16 Jan 2025
10 Jan 2025
By
This website is intended for Hong Kong investors only. Your use of this website means you agree to our Terms of use. This website is strictly for informational purposes only and does not constitute a representation that any investment strategy is suitable or appropriate for an investor’s individual circumstances. In 2018, Global X was acquired by Mirae Asset Global Investments and Mirae Asset Global Investments Co., Ltd. is the parent company of Mirae Asset Global Investments (Hong Kong) Limited.
The information contained in this website is for information purposes only and does not, constitute any recommendations, offer or solicitation to buy, sell or subscribe to any securities or financial instruments in any jurisdiction. Investment involves risk. It cannot be guaranteed that the performance of the Product will generate a return and there may be circumstances where no return is generated or the amount invested is lost. Past performance is not indicative of future performance.
Before making any investment decision to invest in the Product, investors should read the Product’s prospectus for details and the risk factors. Investors should ensure they fully understand the risks associated with the Product and should also consider their own investment objective and risk tolerance level. Investors are advised to seek independent professional advice before making any investments.
Certain information contained in this website is compiled from third party sources. Whilst Mirae Asset Global Investments (Hong Kong) Limited (“Mirae Asset HK”), the Manager of the Product, has, to the best of its endeavor, ensured that such, information is accurate, complete and up-to-date, and has taken care in accurately reproducing the information. Mirae Asset HK accepts no liability for, any loss or damage of any kind resulting out of the unauthorized use of this website.
The Products are not sponsored, endorsed, issued, sold or promoted by their index providers. For details of an index provider including any disclaimer, please refer to the relevant Product’s offering documents.
The contents of this website is prepared and maintained by Mirae Asset Global Investments (Hong Kong) Limited and has not been reviewed by the Securities and Futures Commission of Hong Kong.